Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Colorectal Cancer Drug Policy Will Not Limit Current Off-Label Coverage

This article was originally published in The Pink Sheet Daily

Executive Summary

The Centers for Medicare & Medicaid Services releases its final national coverage determination for Avastin, Erbitux, Eloxatin and Camptosar. The final determination is in line with the draft NCD, covering off-label indications that are included in certain major compendia and are part of nine National Cancer Institute clinical trials.
Advertisement

Related Content

CMS’ Use Of Data From “Coverage With Evidence Development” Process To Vary
CMS’ Use Of Data From “Coverage With Evidence Development” Process To Vary
Off-Label Cancer Studies Only Covered When Drugs Are Not Free, CMS Says
CMS Developing Guidance On Coverage Decisions For Clinical Trials
CMS To Fund Clinical Trials Evaluating Off-Label Use Of Avastin, Erbitux
CMS To Fund Clinical Trials Evaluating Off-Label Use Of Avastin, Erbitux

Topics

Advertisement
UsernamePublicRestriction

Register

PS060976

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel